06-22-2018 12:58 PM CET - Health & Medicine

Injectable Drug Delivery Market is Dominated By Hospitals & Clinics With 62.6% Market Share In 2018, Growing At A CAGR Of 12.5% And Will Cross USD 693,323.05 Million By 2025

Press release from: Data Bridge Market Research
Injectable Drug Delivery Market 2024
Injectable Drug Delivery Market 2024
Data Bridge Market Research offerings publish report of “Global Injectable Drug Delivery Market” Avail 10% Discount on Direct Purchase Or kindly send the email @ sopan.gedam@databridgemarketresearch.com

Global Injectable Drug Delivery Market is expected to reach USD 789.7 billion by 2024 from USD 330.6 billion in 2016, at a CAGR of 11.5% in the forecast period 2017 to 2024. The new market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024. Injectable drug delivery market has the largest market segment in Drug delivery market.

Click Here For Free Sample Report @: databridgemarketresearch.com/request-a-sample/?dbmr=globa...

Recent Developments: Global Injectable Drug Delivery Market
The major factors driving the growth of this market are the increasing use of biologics, rising prevalence of chronic diseases, increasing occurrence of needle stick injuries, and the benefits of injections (convenience, ease of use, and reduced pain). These factors increase the demand for devices such as safety syringes, prefilled syringes, and auto-disabled syringes. On the other hand, safety concerns regarding the use of injectables, increased risk of blood-borne infections due to injectables, and presence of other drug delivery methods (such as oral and transdermal) may hinder the growth of the market.

Geographic Segmentation:

Based on geography the market is segmented into 5 geographical regions, North North America, Europe, Asia-Pacific, South America and Rest of the world. In 2017, North America is expected to account for the largest share of this market, followed by Europe. The geographical regions are further segmented into 24 major countries such as U.S. Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Belgium, Turkey, Japan, China, Singapore, Brazil, India, Russia, and South Africa.

Company Share Analysis:

The report also includes company’s share analysis for the major companies operating in this market by major regions as North America, Europe and Asia Pacific. The details of mergers and acquisitions, product launches, expansions, and product life cycle matrix are also a part of this report. Some of the major players operating in the Global Injectable drug delivery market are Baxter International, Inc., Becton, Dickinson and Company, Gerresheimer AG, Pfizer, Inc., Schott AG, Alkermes Plc., Eli Lilly and Company, Sandoz, Terumo Corporation, and Teva Pharmaceuticals Industries Ltd. among others

Have Any Query? Ask Our Expert: databridgemarketresearch.com/inquire-before-buying/?dbmr=...

Company Analysis:

The global injectable drug delivery market is highly concentrated to a few big players and rest to local players who cater to domestic markets only. Becton, Dickinson and Company dominated the injectable drug delivery market accounting for a highest market share in 2016, followed by Pfizer Inc., and Baxter. Other players in this market include Gerresheimer AG, Eli Lilly and Company, Terumo Corporation, Sandoz, Bespak, Teva Pharmaceutical Industries Ltd., B.Braun, Sun Pharma, SHL Group, MGlas, Owen Mumford Ltd., Alkermes, Antares Pharma, Unilife Corporation, and Terumo Corporation among others holds 24.7% of the global injectable drug delivery market in 2016.

Becton, Dickinson and Company:

Founded in 1897 as Becton, Dickinson and Company and head quartered in New Jersey, U.S. is focused on developing, manufacturing and sales of medical supplies, devices, laboratory equipment and diagnostic products. The company operates through two business segments: BD Medical and BD Life Sciences.

Recent Developments:

In August 2016, BD (Becton, Dickinson and Company), a leading global medical technology company, announced that it has received U.S. Food and Drug Administration (FDA) clearance for its new syringe for patients using Humulin R U-500 insulin vials.

In Dec 2016, BD (Becton, Dickinson and Company) announced the launch of the BD Neopak 2.25 mL prefillable glass syringe, specifically designed for bio pharmaceutical manufacturers that develop, manufacture and market high-value and sensitive biologic drugs that require higher quality levels and performance to treat chronic diseases such as, rheumatoid arthritis, psoriasis, lupus, and severe asthma.

Incorporated in June 1942 and headquartered in New York, U.S. Pfizer Inc., is engaged in discovering, developing and, manufacturing of healthcare products. Pfizer Inc., operates through two segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The Company’s IH segment concentrates on creating and commercializing immunizations and prescriptions that enhance patients’ lives, and in addition products for the end user health care.

Recent Developments:

In March 2017, Pfizer Inc. and Merck announced the FDA approval of BAVENCIO (avelumab) Injection, for intravenous use which is used for the treatment of adults and pediatric patients and with metastatic Merkel cell carcinoma (mMCC).

In February 2017, EMD Serono of Merck KGaA, Darmstadt, Germany, in the US and Canada, and Pfizer Inc. announced the US Food and Drug Administration (FDA) approval of Biologics License Application (BLA) for avelumab as a treatment for patients with locally advanced or metastatic urothelial carcinoma (mUC) with disease progression on or after platinum-based therapy.

Purchase Full Report @ databridgemarketresearch.com/reports/global-injectable-dr...

Other Market Insights:

North America injectable drug delivery market is expected to reach USD 354.5 billion by 2024 from USD 154.0 billion in 2016, at a CAGR of 11.0% in the forecast period 2017 to 2024.

Read More: databridgemarketresearch.com/reports/north-america-inject...

About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process

Data Bridge Market Research
Tel: +1-888-387-2818
Email: sopan.gedam@databridgemarketresearch.com

This release was published on openPR.
News-ID: 1094211 • Views: 146
More releasesMore releases

You can edit or delete your press release here: